| Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the … A Egeberg, NAL Rosenø, D Thein, EH Lørup, ML Nielsen, L Nymand, ... Seminars in Arthritis and Rheumatism 53, 151979, 2022 | 69 | 2022 |
| Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment–a … D Thein, NAL Rosenø, JT Maul, JJ Wu, L Skov, LE Bryld, MK Rasmussen, ... Journal of Investigative Dermatology 143 (11), 2211-2218. e4, 2023 | 13 | 2023 |
| Exploring disease comorbidities and temporal disease progression of psoriasis: an observational, retrospective, multi-database, cohort study NAL Rosenø, EH Lørup, C Richardson, I Alarcon, A Egeberg British Journal of Dermatology 188 (3), 372-379, 2023 | 12 | 2023 |
| Biomarkers of systemic inflammation are associated with disease severity and metabolic syndrome in patients with hidradenitis suppurativa N Holgersen, VW Nielsen, NAL Rosenø, JP Thyssen, A Egeberg, ... JAAD international 15, 170-178, 2024 | 7 | 2024 |
| Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study HC Ring, J Thorsen, B Kirby, JR Ingram, NAL Rosenø, N Holgersen, ... British Journal of Dermatology 190 (5), 769-771, 2024 | 7 | 2024 |
| Drug Survival of Biologics in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis JP Pham, NAL Rosenø, G Roccuzzo, RC Saal, A Egeberg, HC Ring, ... Journal of the American Academy of Dermatology, 2024 | 4 | 2024 |
| Genetic Susceptibility to Hidradenitis Suppurativa and Predisposition to Cardiometabolic Disease VW Nielsen, OB Vad, N Holgersen, C Paludan-Müller, LM Monfort, ... JAMA dermatology, 2024 | 3 | 2024 |
| Psychiatric co‐morbidity in patients with hidradenitis suppurativa: A cross‐sectional study of clinical characteristics and burden of disease N Holgersen, VW Nielsen, HC Ring, NAL Rosenø, A Egeberg, ... JEADV Clinical Practice 2 (4), 994-1004, 2023 | 3 | 2023 |
| Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study D Thein, NAL Rosenø, ML Nielsen, LE Kristensen, JT Maul, JJ Wu, ... JEADV Clinical Practice 2 (4), 857-863, 2023 | 1 | 2023 |
| Usage of digital information and communications technologies in patients with hidradenitis suppurativa NH Pedersen, VW Nielsen, N Holgersen, NAL Rosenø, JP Thyssen, ... JEADV Clinical Practice, 0 | 1 | |
| The Copenhagen Hidradenitis Suppurativa Cohort: Insights from the First 8 Years N Holgersen, VW Nielsen, NAL Rosenø, HC Ring, S Holm Nielsen, ... Dermatology 240 (5-6), 917-921, 2024 | | 2024 |
| 52793 Usage of digital information technologies in patients with hidradenitis suppurativa N Pedersen, V Nielsen, N Holgersen, N Rosenø, J Thyssen, A Egeberg, ... Journal of the American Academy of Dermatology 91 (3), AB352, 2024 | | 2024 |
| Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first-or second-line IL-17A inhibitor treatment: a Danish population-based cohort study RL Hansen, TS Jørgensen, A Egeberg, NAL Rosenø, M Skougaard, ... Rheumatology 63 (6), 1593-1598, 2024 | | 2024 |
| 33251 Exploring temporal disease progression and comorbidities in psoriatic disease NAL Rosenø, EH Lørup, I Alarcon Journal of the American Academy of Dermatology 87 (3), AB59, 2022 | | 2022 |
| 33894 Drug survival 2.0–Real-world dosing of biologics for psoriasis D Thein, NAL Rosenø Journal of the American Academy of Dermatology 87 (3), AB44, 2022 | | 2022 |
